MYGN vs PAYX · rev $824.5M vs P/E 22, rev $6.51B
Myriad Genetics Inc (MYGN) versus Paychex Inc (PAYX) — a side-by-side from cached financials, not a winner call.
Myriad Genetics Inc (MYGN) is a diagnostics & research company listed on NASDAQ.
Paychex Inc (PAYX) is a software - application company listed on NASDAQ.
Latest reported MYGN revenue for 2025-12-31 was $824.5M. Net income was -$365.9M. Revenue was down 1.6% from 2024-12-31 to 2025-12-31. MYGN currently screens at market cap $413.7M.
Latest reported PAYX revenue for 2026-05-31 was $6.51B. Net income was $1.76B. Revenue was up 16.9% from 2025-05-31 to 2026-05-31. PAYX currently screens at market cap $34.96B and trailing P/E 21.5.
MYGN currently screens at market cap $413.7M. PAYX currently screens at market cap $34.96B and trailing P/E 21.5.
Not investment advice. Open the MYGN and PAYX stock pages for the full models.
Not investment advice.